How should I transition a patient with type 2 diabetes mellitus who is on metformin and insulin glargine (Lantus) to a regimen of metformin and a sodium‑glucose cotransporter‑2 (SGLT2) inhibitor?

Transitioning from Metformin + Lantus to Metformin + SGLT2 Inhibitor

You should reduce or discontinue the Lantus dose when adding an SGLT2 inhibitor to prevent hypoglycemia, then titrate the insulin down gradually based on glucose monitoring while the SGLT2 inhibitor is initiated. 1

Step-by-Step Transition Algorithm

1. Pre-Transition Assessment

Check the patient's eGFR first – this determines whether you can even use an SGLT2 inhibitor:

• eGFR ≥20 ml/min/1.73 m²: Safe to initiate SGLT2 inhibitor 2, 3
• eGFR <20 ml/min/1.73 m²: Do not initiate (though can continue if already on one)

2. Initial Insulin Adjustment

The critical safety step: Reduce insulin BEFORE or SIMULTANEOUSLY with SGLT2 inhibitor initiation to avoid hypoglycemia 1:

• If patient is at glycemic target: Reduce Lantus dose by 20-30% when starting SGLT2 inhibitor
• If patient is above glycemic target: You have more flexibility – can reduce by 10-20% or maintain dose initially, but monitor closely

The KDIGO guidelines explicitly state: "For patients in whom additional glucose-lowering may increase risk for hypoglycemia (e.g., those treated with insulin or sulfonylureas and currently meeting glycemic targets), it may be necessary to stop or reduce the dose of an antihyperglycemic drug other than metformin to facilitate addition of an SGLT2i." 1

3. SGLT2 Inhibitor Selection and Initiation

Choose an SGLT2 inhibitor with documented cardiovascular and kidney benefits 1:

• Empagliflozin, canagliflozin, or dapagliflozin are preferred based on outcomes data
• Start at standard doses per FDA labeling
• Consider eGFR-specific dosing (though glycemic efficacy decreases below eGFR 45, cardiovascular/kidney benefits persist) 4

4. Insulin Titration Schedule

Week 1-2 after SGLT2 inhibitor initiation:

• Monitor fasting and pre-dinner glucose daily
• If fasting glucose remains <100 mg/dL: Reduce Lantus by additional 2-4 units
• If fasting glucose 100-130 mg/dL: Maintain current dose
• If fasting glucose >180 mg/dL: May need to slow insulin reduction

Week 3-4:

• Continue reducing Lantus by 10-20% every 1-2 weeks as tolerated
• Goal: Minimize or discontinue insulin if glycemic targets can be maintained on metformin + SGLT2 inhibitor alone

Many patients can eventually discontinue basal insulin entirely when SGLT2 inhibitors are combined with metformin, particularly if they were not severely insulin-deficient to begin with.

5. Monitoring Requirements

Glucose monitoring:

• Check fasting glucose daily during transition (first 2-4 weeks)
• Check pre-dinner glucose if experiencing afternoon hypoglycemia
• Target fasting glucose 80-130 mg/dL (individualize based on patient factors)

Hypoglycemia education:

• The risk is highest in the first 2 weeks of transition
• Patients should recognize symptoms and have glucose tablets available
• If hypoglycemia occurs, further reduce Lantus immediately

Volume status assessment 1:

• Counsel patients about symptoms of volume depletion (dizziness, orthostasis)
• If patient is on diuretics, consider reducing diuretic dose before starting SGLT2 inhibitor
• Follow up within 1-2 weeks to assess volume status

eGFR monitoring 1:

• Expect a small, reversible eGFR decline (2-5 ml/min) in first 2-4 weeks – this is hemodynamic and NOT a reason to stop the drug
• Recheck eGFR at 2-4 weeks, then every 3-6 months
• Continue SGLT2 inhibitor even if eGFR falls below 20 ml/min/1.73 m² once initiated, unless dialysis is started 1, 5

6. Additional Considerations

Ketoacidosis risk 1:

• Educate patients to withhold SGLT2 inhibitor during prolonged fasting, surgery, or critical illness
• This is particularly important as you reduce insulin, which provides some ketoacidosis protection

If glycemic targets are not met after insulin is minimized/discontinued 2, 1:

• Add a GLP-1 receptor agonist as the next step (preferred over restarting/increasing insulin)
• GLP-1 agonists have documented cardiovascular benefits and low hypoglycemia risk

Common Pitfalls to Avoid

1. Not reducing insulin proactively: Waiting to see what happens leads to hypoglycemia. Reduce insulin at the start.

2. Stopping SGLT2 inhibitor due to small eGFR dip: A 2-5 ml/min decline is expected and hemodynamic – don't discontinue 1

3. Initiating SGLT2 inhibitor in patients with eGFR <20: Check kidney function first 2, 3

4. Forgetting volume status assessment: Especially critical in elderly patients or those on diuretics 1

5. Not continuing metformin: Keep metformin unless contraindicated (eGFR <30) – it remains first-line therapy alongside SGLT2 inhibitors 1, 2